FDA
-
-
-
-
-
-
-
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
-
-
-
-
-
-
-
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
-
-
-
-
-
-
-
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
-
-
-
-
-
-
-
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
-
-
-
-
-
-
-
Organon (OGN) Completes Acquisition of Dermavant
-
-
-
-
-
-
-
Organon (OGN) and Samsung Bioepis Announce FDA Acceptance of sBLA for Interchangeability Designation for HADLIMA
-
-
-
-
-
-
-
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vagino
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

